CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Due to CML cell intra-clonal heterogeneity, and LSC resistance to TKIs, we compared the intracellular uptake of nilotinib in both CD34+ cells and PMN from the same patient.